Endpoints News 30. März 2026 #ACC26: Kardigan's repeat dosing of blood pressure drug has no benefit over single shot
Endpoints News 30. März 2026 #AAD26: Sanofi reports underwhelming Phase 3 OX40 data in eczema, second case of Kaposi’s sarcoma
Endpoints News 29. März 2026 #ACC26: Merck leans toward lower Winrevair dose in Phase 3 trial for rare form of heart failure
Endpoints News 28. März 2026 #AAD26: Tanabe’s Phase 3 win for drug targeting rare diseases that cause pain upon light exposure
Endpoints News 28. März 2026 A week of bolt-on deals; Wave crashes on obesity data; Sanofi partners with TCE startup; and more
Endpoints News 27. März 2026 CHMP recommends subcutaneous form of Sanofi's Sarclisa and four new drugs
Endpoints News 27. März 2026 AnaptysBio spins out biotech operations; Affibody's data in hidradenitis suppurativa
Endpoints News 27. März 2026 AstraZeneca’s in vivo CAR-T led to early responses, but one death in China trial
Endpoints News 27. März 2026 Novartis to spend up to $2B on Excellergy and its next-gen Xolair candidate
Endpoints News 27. März 2026 AstraZeneca’s COPD antibody gets Phase 3 wins in broader-than-expected population